Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rivaroxaban

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    122 result(s) found for: Rivaroxaban. Displaying page 4 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2016-002291-27 Sponsor Protocol Number: RIVAR-CTP-01 Start Date*: 2016-11-07
    Sponsor Name:Aalborg University Hospital
    Full Title: Randomized trial of aspirin versus rivaroxaban after replacement of the aortic valve with a biological valve prosthesis
    Medical condition: Aortic valve stenosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10002918 Aortic valve stenosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001534-19 Sponsor Protocol Number: APHP200015 Start Date*: 2021-05-21
    Sponsor Name:AP-HP/DRCI
    Full Title: Direct oral Anticoagulants for Prevention of lEft ventRIcular Thrombus after anterior acute myocardial InFarction
    Medical condition: Left ventricular (LV) thrombus after acute myocardial infarction (AMI)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001723-12 Sponsor Protocol Number: ARIVA_venous Start Date*: 2020-05-28
    Sponsor Name:Universitätsspital Zürich, Klinik für Angiologie
    Full Title: Aspirin® plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic syndrome
    Medical condition: Post-thrombotic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003299-11 Sponsor Protocol Number: RD2018-41 Start Date*: 2018-10-22
    Sponsor Name:East and North Hertfordshire NHS Trust
    Full Title: Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy (DAPT) improve thrombotic status in acute coronary syndrome (ACS)
    Medical condition: Acute Coronary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-001062-15 Sponsor Protocol Number: BAY59-7939/16320 Start Date*: 2013-06-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label, international, multicenter, interventional study exploring the efficacy of once-daily oral rivaroxaban (BAY 59-7939) for the treatment of left atrial/left atrial appendage thrombus i...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    16.1 10007541 - Cardiac disorders 10003662 Atrial flutter PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000610-10 Sponsor Protocol Number: RivAsA Start Date*: 2020-01-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Effects of low-dose Rivaroxaban combined with low-dose Aspirin versus low-dose aspirin alone on in vivo platelet Activation, endothelial function and inflammation in type 2 diabetic patients with s...
    Medical condition: type 2 diabetic patients with stable peripheral or carotid artery disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10067825 Peripheral arterial disease LLT
    21.0 10027433 - Metabolism and nutrition disorders 10053247 Insulin-requiring type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000794-23 Sponsor Protocol Number: 49RC19_0034 Start Date*: 2019-07-26
    Sponsor Name:CHU ANGERS
    Full Title: AntiCoagulants et COGnition (essai ACCOG) : Essai contrôlé randomisé en simple aveugle comparant les effets neurocognitifs du rivaroxaban par rapport à un antagoniste de la vitamine K
    Medical condition: fibrillation atriale non valvulaire
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    20.0 10007541 - Cardiac disorders 10007521 Cardiac arrhythmias HLGT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001478-16 Sponsor Protocol Number: CONKO-011_AIO-SUP-0115/ass. Start Date*: 2016-01-05
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Rivaroxaban in the treatment of venous thrombembolism (VTE) in cancer patients – a randomized phase III Study
    Medical condition: Tumor patients with active cancer and newly diagnosed thrombembolic events were randomised to receive either Rivaroxaban or the standard treatment with low-molecular heparine
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2013-004575-13 Sponsor Protocol Number: TRAPS-1.5 Start Date*: 2014-10-29
    Sponsor Name:Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari-Università di Padova
    Full Title: A prospective, randomized clinical trial comparing Rivaroxaban vs warfarin in high risk patients with antiphospholipid syndrome (TRAPS).
    Medical condition: THROMBOEMBOLISM PREVENTION
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005589-37 Sponsor Protocol Number: RMRHS0095 Start Date*: 2013-03-08
    Sponsor Name:University of Warwick
    Full Title: select-d: Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism
    Medical condition: Venous Thromboembolism and Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10007050 Cancer LLT
    14.1 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000353-26 Sponsor Protocol Number: SAFE-SSPE Start Date*: 2021-09-20
    Sponsor Name:Bern University Hospital
    Full Title: Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Placebo-Controlled Non-Inferiority Trial
    Medical condition: Isolated subsegmental pulmonary embolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001443-31 Sponsor Protocol Number: 1801 Start Date*: 2018-11-21
    Sponsor Name:Leiden University Medical Center
    Full Title: DOAC Levels prior to Incision study: DALI study
    Medical condition: No medical condition will be investigated. This study will only investigate DOAC levels during surgery. Patients who use DOACs are patients with venous thrombosis and atrial fibrillation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019764-36 Sponsor Protocol Number: SAP-02 Start Date*: 2011-02-03
    Sponsor Name:JOSEP ORDI-ROS
    Full Title: RIVAROXABAN VERSUS ACENOCUMAROL EN LA PROFILAXIS SECUNDARIA DEL SÍNDROME ANTIFOSFOLÍPIDO:UN ESTUDIO MULTICÉNTRICO, PROSPECTIVO Y RANDOMIZADO.
    Medical condition: Sindrome Antifosfolípido
    Disease: Version SOC Term Classification Code Term Level
    13 10002817 Síndrome antifosfolípido LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004784-53 Sponsor Protocol Number: APHP200002 Start Date*: 2022-07-19
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: Rivaroxaban versus standard of care for patients with excessive atrial ectopy or short atrial runs and high embolism risk SHORT RUN AF
    Medical condition: excessive atrial ectopy or short atrial runs and high embolism risk
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10042601 Supraventricular ectopics LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003621-28 Sponsor Protocol Number: 5072018 Start Date*: 2019-07-23
    Sponsor Name:IUCPQ
    Full Title: Short-Term Anticoagulation versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES study.
    Medical condition: Device thrombosis at 2 months and 12 months after left atrial appendage closure (LAAC) Ischemic events (stroke, TIA) at 2-month and 1-, 2-, 3-, 4-and 5-year follow-up Bleeding events at 2-month an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10014523 Embolism and thrombosis HLGT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10047065 - Vascular disorders 10005103 Bleeding LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002529-39 Sponsor Protocol Number: PHRC2015-07 Start Date*: 2017-08-30
    Sponsor Name:CHU Angers
    Full Title: Intérêt de l’administration de charbon Activé pour les patients ayant un geste invasif reporté dû à un traitement Anticoagulant Oral Direct
    Medical condition: fibrillation auriculaire ou une maladie veineuse thromboembolique
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002084-20 Sponsor Protocol Number: Version_1.0_MP_and_anticoagulants Start Date*: 2011-07-28
    Sponsor Name:Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie
    Full Title: A prospective, randomized, controlled open-label trial to investigate the effects of 10mg rivaroxaban or 110mg dabigatran on microparticle formation in critically ill patients compared to age-& sex...
    Medical condition: The effect of the used IMPs should be investigated in critically ill patients and healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004913-11 Sponsor Protocol Number: 111075 Start Date*: 2021-02-18
    Sponsor Name:Radboudumc
    Full Title: genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease’
    Medical condition: Symptomatic or stable pheripheral artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001190-40 Sponsor Protocol Number: P110150 Start Date*: 2018-05-16
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10036206 Portal vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005110-17 Sponsor Protocol Number: PhRisCo-study Start Date*: 2021-10-07
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA
    Full Title: Pharmacodynamic and pleiotropic effects of Rivaroxaban in Coronary Artery Disease and Atrial Fibrillation
    Medical condition: stable CAD; history of atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    20.0 10007541 - Cardiac disorders 10021279 IHD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 08:31:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA